Business Context and Reporting Period
Company: NUR Macroprinters Ltd. (Nasdaq-SCM: NURM)
Filing Type: Form 6-K (Press Release)
Reporting Period: Third Quarter ended September 30, 2004 (Unaudited)
Business Overview: Leading supplier of wide-format inkjet production printing systems for out-of-home advertising materials.
Key Financial Metrics
| Metric | Q3 2004 | Q3 2003 (GAAP) | Q3 2003 (Non-GAAP) |
|---|---|---|---|
| Revenue | $19.9 million | $17.1 million | $17.1 million |
| Gross Margin | 33.8% | 15.4% | 41.8% |
| Operating Income | $10,000 | ($4.84) million | ($328,000) |
| Net Loss | ($798,000) | ($5.46) million | ($948,000) |
| EPS (Diluted) | ($0.03) | ($0.32) | ($0.05) |
Year-to-Date (Nine Months Ended Sept 30, 2004):
- Revenue: $58.9 million (up 24% vs. prior year).
- Net Loss: ($1.54) million.
- Cash and Cash Equivalents: $9.99 million (as of Sept 30, 2004).
- Total Debt: $39.65 million ($12.03 million short-term + $27.62 million long-term).
Material Changes vs. Prior Period
- Revenue Growth: Q3 revenue increased 16% year-over-year, driven by increased Tempo and Fresco II sales in the USA. However, revenue decreased 3% sequentially from Q2 2004.
- Margin Compression: Gross margins declined from 40% in Q2 2004 to 33.8% in Q3 2004. Management attributes this to pricing pressure from a major competitor who reduced prices by up to 40%.
- Profitability: The company reported a net loss of $798,000 for Q3 2004, compared to a net profit of $233,000 in Q2 2004. This marks a return to profitability challenges despite meeting unit sales targets.
- Balance Sheet: Accounts receivable increased to $25.65 million from $18.57 million at year-end 2003. Inventories rose to $20.92 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- New Product Launch: The new NUR Expedio wide-format UV inkjet printer is expected to be released in Q4 2004. Management expects meaningful revenue and improved gross margins from this product starting in Q4.
- 2004 Full Year Guidance:
- Revenue: $80-82 million.
- Net Loss: ($0.7) to ($1.0) million (revised lower due to gross margin pressure).
- 2005 Full Year Guidance:
- Revenue: $91-93 million.
- Gross Margins: 37-39%.
- Net Profit: $3-5 million.
- Management Changes: Nachum Korman, President of NUR America Inc., stepped down. CEO David Amir is serving as acting President.
Risks and Contingencies
- Debt Covenant Breach: The company failed to meet certain financial covenants in its loan agreements based on Q3 results. It is currently seeking waivers from banks.
- Contingency: If waivers are not obtained, long-term debt of $27.6 million will be reclassified as short-term debt, increasing total short-term debt to $42.7 million.
- Competition: Continued pricing pressure from competitors remains a risk to gross margins.
- Forward-Looking Statements: Actual results may differ materially due to economic conditions, demand declines, or inability to secure lender waivers.
Investor Verification Checklist
- Debt Covenant Waivers: Confirm whether the company has successfully obtained waivers from its lenders to prevent the reclassification of $27.6 million in long-term debt to short-term debt.
- Expedio Launch Timeline: Verify the actual release date and initial sales traction of the NUR Expedio printer in Q4 2004.
- Pricing Environment: Monitor competitor pricing strategies to assess if the 34% gross margin is sustainable or if further compression is likely.
- Leadership Transition: Track the appointment of a permanent replacement for the President of NUR America Inc.
- Cash Flow: Review the impact of the increased accounts receivable ($25.65 million) on working capital and liquidity.